Abstract
In a multicenter, open-label study conducted in Japan between July 2004 and May 2005, Nakayamada et al. tested the safety and efficacy of mizoribine for the treatment of primary Sjögren's syndrome (pSS). Mizoribine 50 mg was administered three times a day for 16 weeks to 59 patients with pSS, 7 of whom withdrew because of adverse drug reactions; however, no serious adverse events were noted. In the 48 patients who completed the study, an increase from baseline in median salivary secretion volume, evaluated using the Saxon test, was apparent at week 8 and was significant at week 16 (P <0.05). At 16 weeks, significant improvements from baseline were also seen in patients' assessments of dry mouth and dry eyes, physicians' assessment of oral sicca symptoms, labioangular sicca symptoms and physicians' overall assessment, all measured using a 10 cm visual analog scale. The findings suggest that mizoribine could be an effective treatment for pSS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Routsias JG et al. (2004) The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases. Clin Chim Acta 340: 1–25
Mitsias DI et al. (2006) The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjögren's syndrome (autoimmune epithelitis). Lupus 15: 255–261
Mavragani CP et al. (2006) The management of Sjögren's syndrome. Nat Clin Pract Rheumatol 2: 252–261
Willeke P et al. (2007) Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther 9: R115
Meijer JM et al. (2007) The future of biologic agents in the treatment of Sjögren's syndrome. Clin Rev Allergy Immunol 32: 292–297
Ramos-Casals M and Brito-Zerón P (2007) Emerging biological therapies in primary Sjögren's syndrome. Rheumatology (Oxford) 46: 1389–1396
Jain J et al. (2001) VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci 90: 625–637
Mizuno K et al. (1974) Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 27: 775–782
Stypinski D et al. (2007) Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 63: 459–468
Nakayamada S et al. (2003) Efficacy of mizoribine treatment in patients with Sjögren's syndrome: an open pilot trial. Mod Rheumatol 13: 339–345
Acknowledgements
The summary was written by Sarah Price, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Moutsopoulos, H., Fragoulis, G. Is mizoribine a new therapeutic agent for Sjögren's syndrome?. Nat Rev Rheumatol 4, 350–351 (2008). https://doi.org/10.1038/ncprheum0823
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0823
This article is cited by
-
Multiple bone fracture due to Fanconi’s syndrome in primary Sjögren’s syndrome complicated with organizing pneumonia
Rheumatology International (2009)